Exscientia PLC (EXAI)
5.03
+0.27
(+5.67%)
USD |
NASDAQ |
Jun 14, 16:00
5.00
-0.03
(-0.60%)
After-Hours: 20:00
Exscientia Net Income (Quarterly): -26.65M for March 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -26.65M |
December 31, 2023 | -51.09M |
September 30, 2023 | -39.52M |
June 30, 2023 | -45.02M |
March 31, 2023 | -45.75M |
December 31, 2022 | -45.96M |
September 30, 2022 | -41.75M |
June 30, 2022 | -36.05M |
Date | Value |
---|---|
March 31, 2022 | -20.79M |
December 31, 2021 | -27.07M |
September 30, 2021 | -7.007M |
June 30, 2021 | -25.99M |
March 31, 2021 | -7.539M |
December 31, 2020 | -8.880M |
September 30, 2020 | -10.82M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-51.09M
Minimum
Dec 2023
-7.007M
Maximum
Sep 2021
-29.33M
Average
-27.07M
Median
Dec 2021
Net Income (Quarterly) Benchmarks
Akero Therapeutics Inc | -53.34M |
Adaptimmune Therapeutics PLC | -48.50M |
Biodexa Pharmaceuticals Plc | -- |
Verona Pharma PLC | -25.79M |
NuCana PLC | -8.673M |
Net Income (Quarterly) Related Metrics
Revenue (Quarterly) | 6.710M |
Total Expenses (Quarterly) | 42.06M |
EPS Diluted (Quarterly) | -0.2156 |
Enterprise Value | 410.49M |
Gross Profit Margin (Quarterly) | -40.02% |
Profit Margin (Quarterly) | -397.1% |
Earnings Yield | -25.94% |
Normalized Earnings Yield | -26.03 |